{"id":745542,"date":"2017-06-02T06:30:00","date_gmt":"2017-06-02T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/"},"modified":"2025-11-07T01:26:29","modified_gmt":"2025-11-07T06:26:29","slug":"with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/","title":{"rendered":"With Nearly Three Years of Follow-Up, KEYTRUDA\u00ae (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma"},"content":{"rendered":"<p class=\"bwalignc\">       Findings Show Durable Responses with KEYTRUDA after Treatment        Concluded: 91 Percent of Patients Who Discontinued Treatment at        Two Years Were Alive Without Progression of Disease after a Median        Follow-Up of Nearly 10 Months     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced updated longer-term overall survival (OS) data from<br \/>\n      KEYNOTE-006, the phase 3 study evaluating KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with<br \/>\n      unresectable or metastatic melanoma. The data showed sustained superior<br \/>\n      survival outcomes for patients receiving KEYTRUDA (monotherapy) compared<br \/>\n      to ipilimumab in patients who were treatment-na\u00efve or received one prior<br \/>\n      line of therapy for the treatment of advanced melanoma. The survival<br \/>\n      benefit was sustained in patients who completed the planned two years of<br \/>\n      treatment with KEYTRUDA. These data will be presented in an oral session<br \/>\n      at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting<br \/>\n      in Chicago on Sunday, June 4, from 9:12 to 9:24 a.m. CDT (Location: Arie<br \/>\n      Crown Theater) (Abstract #9504).\n    <\/p>\n<p>\n      In the longer-term findings to be presented, treatment with KEYTRUDA was<br \/>\n      associated with a 30 percent improvement in survival: 50 percent of<br \/>\n      patients in the KEYTRUDA group (based on a pooled analysis of the two<br \/>\n      doses studied: 10 mg\/kg every two weeks or 10 mg\/kg every three weeks;<br \/>\n      n=556) were alive nearly three years (33.9 months) after starting<br \/>\n      treatment with KEYTRUDA, compared to 39 percent of patients in the<br \/>\n      ipilimumab group (n=278) (HR: 0.70 [95% CI, 0.58-0.86]). In addition,<br \/>\n      KEYTRUDA nearly doubled the rate of progression-free survival (PFS) at<br \/>\n      33.9 months: 31 percent of patients in the KEYTRUDA group were alive and<br \/>\n      their disease had not progressed, compared to 14 percent of patients in<br \/>\n      the ipilimumab group.\n    <\/p>\n<p>\n      \u201cKEYTRUDA continues to demonstrate improved overall survival compared to<br \/>\n      ipilimumab, and the findings to be presented at ASCO reinforce the<br \/>\n      benefit of KEYTRUDA in the treatment of advanced melanoma,\u201d said Dr.<br \/>\n      Roger Dansey, senior vice president and therapeutic area head, oncology<br \/>\n      late-stage development, Merck Research Laboratories.\n    <\/p>\n<p>\n      The KEYTRUDA (pembrolizumab) clinical development program includes more<br \/>\n      than 30 tumor types in more than 500 clinical trials, including more<br \/>\n      than 300 trials that combine KEYTRUDA with other cancer treatments.<br \/>\n      Today, KEYTRUDA is approved for the treatment of advanced melanoma in<br \/>\n      more than 50 countries, including the United States and throughout<br \/>\n      Europe.\n    <\/p>\n<p>\n      \u201cWith longer-term follow-up in this study, we are continuing to see<br \/>\n      superior survival with KEYTRUDA, including in patients whose treatment<br \/>\n      has concluded,\u201d said Dr. Caroline Robert, head of dermatology at Gustave<br \/>\n      Roussy, Villejuif and Paris-Sud University Cancer Campus, Grand Paris.<br \/>\n      \u201cImportantly, these findings also continue to reaffirm the established<br \/>\n      safety profile for KEYTRUDA.\u201d\n    <\/p>\n<p>\n      <b>Key Findings from the KEYNOTE-006 Study<\/b>\n    <\/p>\n<p>\n      KEYNOTE-006 is a global, open-label, randomized, pivotal, phase 3 study<br \/>\n      evaluating KEYTRUDA compared to ipilimumab in patients with unresectable<br \/>\n      stage III or IV advanced melanoma who had either not been treated<br \/>\n      previously (first-line treatment setting) or who had received one prior<br \/>\n      therapy (in the KEYTRUDA arm 34% received prior therapy; in the<br \/>\n      ipilimumab arm, 35% received prior therapy). The study randomized 834<br \/>\n      patients to receive KEYTRUDA 10 mg\/kg every three weeks, KEYTRUDA 10<br \/>\n      mg\/kg every two weeks, or four cycles of ipilimumab 3 mg\/kg every three<br \/>\n      weeks. Treatment continued until unacceptable toxicity or disease<br \/>\n      progression; patients without disease progression could be treated for<br \/>\n      up to 24 months. The co-primary endpoints were PFS and OS; secondary<br \/>\n      endpoints were overall response rate (ORR), duration of response and<br \/>\n      safety, with an exploratory analysis for health-related quality of life<br \/>\n      (QoL). Tumor response was assessed at week 12, then every 6 weeks until<br \/>\n      week 48, then every 12 weeks thereafter per Response Evaluation Criteria<br \/>\n      in Solid Tumors (RECIST) v1.1 by independent, central, blinded<br \/>\n      radiographic review and investigator-assessed, immune-related response<br \/>\n      criteria.\n    <\/p>\n<p>\n      The findings to be presented at ASCO were based on a pooled analysis of<br \/>\n      data from patients receiving the two doses of KEYTRUDA (10 mg\/kg every<br \/>\n      two weeks or 10 mg\/kg every three weeks; n=556). Analyses of these data<br \/>\n      continued to show superior OS, PFS and ORR compared to ipilimumab with<br \/>\n      follow-up of nearly three years (33.9 months). Specifically, long-term<br \/>\n      OS data showed 50 percent of patients in the KEYTRUDA (pembrolizumab)<br \/>\n      treatment arm (n=556) were alive at 33.9 months after starting<br \/>\n      treatment, compared to 39 percent of patients in the ipilimumab arm<br \/>\n      (n=278) (HR: 0.70 [95% CI, 0.58-0.86]). The PFS endpoint showed that 31<br \/>\n      percent of patients in the KEYTRUDA arm were alive and were disease<br \/>\n      progression-free at 33.9 months, compared to 14 percent of patients<br \/>\n      receiving ipilimumab (HR: 0.56 [95% CI, 0.47-0.67]).\n    <\/p>\n<p>\n      ORR, as assessed by investigator, was 42 percent for patients in the<br \/>\n      KEYTRUDA arm (range: 38-46), compared to 16 percent for patients<br \/>\n      receiving ipilimumab (range: 12-21). In patients in the KEYTRUDA arm,<br \/>\n      the complete response rate was 13 percent (95% CI, 11-16) and the<br \/>\n      partial response rate was 29 percent (95% CI, 25-33); in patients in the<br \/>\n      ipilimumab arm, the complete response rate was 3 percent (95% CI, 1-6)<br \/>\n      and the partial response rate was 14 percent (95% CI, 10-18). The<br \/>\n      responses achieved continue to be durable, as the median duration of<br \/>\n      response has not been reached.\n    <\/p>\n<p>\n      Further analyses were conducted to assess the outcomes in patients who<br \/>\n      had completed 94 or more weeks of treatment with KEYTRUDA (n=104\/556)<br \/>\n      and stopped treatment as planned per protocol. After a median follow-up<br \/>\n      of 9.7 months since stopping treatment, the estimated PFS was 91 percent<br \/>\n      (95% CI, 80-96). With longer follow-up, adverse events have remained<br \/>\n      consistent with previously reported safety data. There was one<br \/>\n      treatment-related death in the KEYTRUDA arm. In patients treated with<br \/>\n      KEYTRUDA, immune-mediated adverse events observed in more than 2 percent<br \/>\n      of patients were hypothyroidism (11%), hyperthyroidism (5%), colitis<br \/>\n      (3%), skin disorders (3%), and pneumonitis (2%).\n    <\/p>\n<p>\n      <b>About Melanoma<\/b>\n    <\/p>\n<p>\n      Melanoma, the most serious form of skin cancer, is characterized by the<br \/>\n      uncontrolled growth of pigment-producing cells. The incidence of<br \/>\n      melanoma has been increasing over the past four decades \u2013 approximately<br \/>\n      232,000 new cases were diagnosed worldwide in 2012. In the U.S.,<br \/>\n      melanoma is one of the most common types of cancer diagnosed and is<br \/>\n      responsible for the vast majority of skin cancer deaths. In 2016, an<br \/>\n      estimated 76,380 people are expected to be diagnosed and an estimated<br \/>\n      10,130 people are expected to die of the disease in the U.S. alone. The<br \/>\n      five-year survival rates for advanced or metastatic melanoma (Stage IV)<br \/>\n      are estimated to be 15 to 20 percent.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 500 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single-dose vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b> <b>Indications<br \/>\n      and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA (pembrolizumab) is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is also indicated for the treatment of patients<br \/>\n      with locally advanced or metastatic urothelial carcinoma who have<br \/>\n      disease progression during or following platinum-containing chemotherapy<br \/>\n      or within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 2; permanently discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause immune-mediated nephritis. Nephritis<br \/>\n      occurred in 9 (0.3%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.1%), 3 (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma. In addition,<br \/>\n      myelitis and myocarditis were reported in other clinical trials,<br \/>\n      including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      (pembrolizumab) on any trial, 6 patients (26%) developed<br \/>\n      graft-versus-host-disease (GVHD), one of which was fatal, and 2 patients<br \/>\n      (9%) developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning, one of which was fatal. Cases of fatal<br \/>\n      hyperacute GVHD after allogeneic HSCT have also been reported in<br \/>\n      patients with lymphoma who received a PD-1 receptor\u2013blocking antibody<br \/>\n      before transplantation. These complications may occur despite<br \/>\n      intervening therapy between PD-1 blockade and allogeneic HSCT. Follow<br \/>\n      patients closely for early evidence of transplant-related complications<br \/>\n      such as hyperacute GVHD, severe (Grade 3 to 4) acute GVHD,<br \/>\n      steroid-requiring febrile syndrome, hepatic VOD, and other<br \/>\n      immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients with advanced melanoma; the most common (\u22651%) were<br \/>\n      general physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculopapular rash (1%). The<br \/>\n      most common adverse reactions with KEYTRUDA vs chemotherapy were fatigue<br \/>\n      (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA (pembrolizumab) is excreted in human<br \/>\n      milk. Because many drugs are excreted in human milk, instruct women to<br \/>\n      discontinue nursing during treatment with KEYTRUDA and for 4 months<br \/>\n      after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 500 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=fa897804a05f1de0bfda2eed1a0feeaa\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=260fa5f361671516428c933c3dc264d6\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=d1dd7314bb41dbaa6ec9b9769b5a55d5\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=f6202044f3bcf063f22a1ecb626c0f08\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=e1581e20123f490d4f84009ee37bae99\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=84a09311d494a347916b124bb6fde3ab\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=2ab0c585134a51af322063e773fdf576\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=8776b0f8e3c68777e09e0851a3643d7f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=d413f2603acaaa664482b4654153d29d\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51568738&amp;newsitemid=20170602005183&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=6c3e52317e8eb12fc29b5d78cdadd439\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170602005183r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Elizabeth        Sell, 267-305-3877<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Findings Show Durable Responses with KEYTRUDA after Treatment Concluded: 91 Percent of Patients Who Discontinued Treatment at Two Years Were Alive Without Progression of Disease after a Median Follow-Up of Nearly 10 Months Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated longer-term overall survival (OS) data from KEYNOTE-006, the phase 3 study evaluating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with unresectable or metastatic melanoma. The data showed sustained superior survival outcomes for patients receiving KEYTRUDA (monotherapy) compared to ipilimumab in patients who were treatment-na\u00efve or received one prior line of therapy for the treatment of advanced melanoma. The survival benefit was sustained in patients who completed the planned two years of treatment with KEYTRUDA. These data will be presented in an oral session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[149,53,64,55,289],"class_list":["post-745542","news_item","type-news_item","status-publish","hentry","tag-asco","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>With Nearly Three Years of Follow-Up, KEYTRUDA\u00ae (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"With Nearly Three Years of Follow-Up, KEYTRUDA\u00ae (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Findings Show Durable Responses with KEYTRUDA after Treatment Concluded: 91 Percent of Patients Who Discontinued Treatment at Two Years Were Alive Without Progression of Disease after a Median Follow-Up of Nearly 10 Months Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated longer-term overall survival (OS) data from KEYNOTE-006, the phase 3 study evaluating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with unresectable or metastatic melanoma. The data showed sustained superior survival outcomes for patients receiving KEYTRUDA (monotherapy) compared to ipilimumab in patients who were treatment-na\u00efve or received one prior line of therapy for the treatment of advanced melanoma. The survival benefit was sustained in patients who completed the planned two years of treatment with KEYTRUDA. These data will be presented in an oral session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"19 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\\\/\",\"name\":\"With Nearly Three Years of Follow-Up, KEYTRUDA\u00ae (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-06-02T06:30:00+00:00\",\"dateModified\":\"2025-11-07T06:26:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"With Nearly Three Years of Follow-Up, KEYTRUDA\u00ae (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"With Nearly Three Years of Follow-Up, KEYTRUDA\u00ae (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"With Nearly Three Years of Follow-Up, KEYTRUDA\u00ae (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma - Merck.com","og_description":"Findings Show Durable Responses with KEYTRUDA after Treatment Concluded: 91 Percent of Patients Who Discontinued Treatment at Two Years Were Alive Without Progression of Disease after a Median Follow-Up of Nearly 10 Months Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated longer-term overall survival (OS) data from KEYNOTE-006, the phase 3 study evaluating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with unresectable or metastatic melanoma. The data showed sustained superior survival outcomes for patients receiving KEYTRUDA (monotherapy) compared to ipilimumab in patients who were treatment-na\u00efve or received one prior line of therapy for the treatment of advanced melanoma. The survival benefit was sustained in patients who completed the planned two years of treatment with KEYTRUDA. These data will be presented in an oral session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:29+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"19 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/","name":"With Nearly Three Years of Follow-Up, KEYTRUDA\u00ae (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-06-02T06:30:00+00:00","dateModified":"2025-11-07T06:26:29+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-nearly-three-years-of-follow-up-keytruda-pembrolizumab-data-demonstrated-improved-survival-benefit-compared-to-ipilimumab-in-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"With Nearly Three Years of Follow-Up, KEYTRUDA\u00ae (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a5fc8398-466c-4060-b0c3-41d43fa58288","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/With-Nearly-Three-Years-of-Follow-Up-KEYTRUDA-pembrolizumab-Data-Demonstrated-Improved-Survival-Benefit-Compared-to-Ipilimumab-in-Adv-U17LL.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745542\/revisions"}],"predecessor-version":[{"id":3674900,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745542\/revisions\/3674900"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745542"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}